DE60201437T2 - 2,6-substituierte chromanderivate und ihre verwendung als beta-3 adrenorezeptor agonisten - Google Patents

2,6-substituierte chromanderivate und ihre verwendung als beta-3 adrenorezeptor agonisten Download PDF

Info

Publication number
DE60201437T2
DE60201437T2 DE60201437T DE60201437T DE60201437T2 DE 60201437 T2 DE60201437 T2 DE 60201437T2 DE 60201437 T DE60201437 T DE 60201437T DE 60201437 T DE60201437 T DE 60201437T DE 60201437 T2 DE60201437 T2 DE 60201437T2
Authority
DE
Germany
Prior art keywords
amino
methyl
dihydro
chromen
pyridinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60201437T
Other languages
German (de)
English (en)
Other versions
DE60201437D1 (de
Inventor
J. Stephen O'CONNOR
H. Gaetan LADOUCEUR
H. William BULLOCK
Ann-Marie Campbell
Miao Dai
Robert Dally
Jacques Dumas
N. Holia HATOUM-MOKDAD
Uday Khire
Wendy Lee
Qingjie Liu
B. Derek LOWE
R. Steven MAGNUSON
Ning Qi
E. Tatiana SHELEKHIN
Quanrong Shen
A. Roger SMITH
Ming Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharmaceuticals Corp
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Application granted granted Critical
Publication of DE60201437D1 publication Critical patent/DE60201437D1/de
Publication of DE60201437T2 publication Critical patent/DE60201437T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60201437T 2001-04-23 2002-04-22 2,6-substituierte chromanderivate und ihre verwendung als beta-3 adrenorezeptor agonisten Expired - Fee Related DE60201437T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28571901P 2001-04-23 2001-04-23
US285719P 2001-04-23
US32451801P 2001-09-26 2001-09-26
US324518P 2001-09-26
PCT/US2002/012940 WO2002085891A1 (en) 2001-04-23 2002-04-22 2,6-substituted chroman derivatives useful as beta-3 adrenoreceptor agonists

Publications (2)

Publication Number Publication Date
DE60201437D1 DE60201437D1 (de) 2004-11-04
DE60201437T2 true DE60201437T2 (de) 2005-12-15

Family

ID=26963345

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60201437T Expired - Fee Related DE60201437T2 (de) 2001-04-23 2002-04-22 2,6-substituierte chromanderivate und ihre verwendung als beta-3 adrenorezeptor agonisten

Country Status (9)

Country Link
US (3) US6660752B2 (enExample)
EP (1) EP1389202B1 (enExample)
JP (1) JP2004532227A (enExample)
AR (1) AR035858A1 (enExample)
DE (1) DE60201437T2 (enExample)
DO (1) DOP2002000385A (enExample)
ES (1) ES2230487T3 (enExample)
PE (1) PE20021073A1 (enExample)
WO (1) WO2002085891A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049593A2 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
RU2372344C2 (ru) * 2004-05-05 2009-11-10 Ф. Хоффманн-Ля Рош Аг Арилсульфонилбензодиоксаны, применяемые для модуляции 5-нт6 рецептора, 5-нт2a рецептора или и того, и другого
KR100899061B1 (ko) * 2004-12-21 2009-05-25 에프. 호프만-라 로슈 아게 테트랄린 및 인단 유도체 및 이의 용도
KR20070088798A (ko) * 2004-12-21 2007-08-29 에프. 호프만-라 로슈 아게 크로만 유도체 및 그의 5-ｈｔ 수용체 리간드로서의 용도
WO2006066756A1 (en) 2004-12-21 2006-06-29 F. Hoffmann-La Roche Ag Chroman derivatives and uses thereof in the treatment of cns disorders
CN101119965B (zh) * 2004-12-21 2012-09-26 弗·哈夫曼-拉罗切有限公司 萘满和茚满衍生物及其用途
ATE409179T1 (de) * 2004-12-21 2008-10-15 Hoffmann La Roche Tetralin- und indanderivate und deren anwendungen als 5-ht-antagonisten
JP2008530229A (ja) 2005-02-17 2008-08-07 ワイス シクロアルキル縮合インドール、ベンゾチオフェン、ベンゾフランおよびインデン誘導体
CN101300246A (zh) * 2005-11-03 2008-11-05 弗·哈夫曼-拉罗切有限公司 作为5－ht6抑制剂的芳基磺酰基色满类化合物作为蛋白激酶抑制剂的吲哚基马来酰亚胺衍生物
GB0526252D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
PT2402319T (pt) 2006-03-31 2017-12-11 Novartis Ag Inibidores de dgat
JP2009541249A (ja) * 2006-06-20 2009-11-26 エフ．ホフマン−ラ ロシュ アーゲー アリールスルホニルナフタレン誘導体およびその使用
WO2007147762A1 (en) * 2006-06-20 2007-12-27 F. Hoffmann-La Roche Ag Arylsulfonamidyl tetralin derivatives and uses thereof
MX2008015843A (es) * 2006-06-20 2009-01-09 Hoffmann La Roche Derivados de tetralina e indano y usos de los mismos.
SG2014012926A (en) * 2011-08-30 2014-06-27 Chdi Foundation Inc Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
US9981931B2 (en) 2013-01-09 2018-05-29 BASF Agro B.V. Process for the preparation of substituted oxiranes and triazoles
EP3013810A1 (en) * 2013-06-24 2016-05-04 Lupin Limited Chromane and chromene derivatives and their use as crac modulators
US10512267B2 (en) 2013-07-08 2019-12-24 BASF Agro, B.V. Compositions comprising a triazole compound and a biopesticide
EA201990522A1 (ru) * 2013-12-12 2019-07-31 Басф Агро Б.В. Способ получения замещенных оксиранов и триазолов
EP3269245B1 (en) 2014-06-25 2023-08-16 BASF Agro B.V. Pesticidal compositions
CN106660979B (zh) 2014-07-08 2020-07-07 巴斯夫农业公司 制备取代的环氧乙烷类和三唑类的方法
MX372995B (es) 2014-07-17 2020-04-13 Chdi Foundation Inc Metodos y composiciones para el tratamiento de trastornos relacionados con vih.
AU2015342067B2 (en) 2014-11-07 2019-10-31 Basf Se Pesticidal mixtures
BR112017023932A2 (pt) 2015-05-08 2018-07-17 Basf Agro Bv processo para a preparação de epóxido de terpinoleno
CN107848922A (zh) 2015-05-08 2018-03-27 巴斯夫农业公司 柠檬烯‑4‑醇的制备方法
US10336733B2 (en) 2015-11-30 2019-07-02 Merk Sharp & Dohme Corp. Aryl acylsulfonamides as BLT1 antagonists
US10370368B2 (en) 2015-11-30 2019-08-06 Merck Sharp & Dohme Corp. Aryl acylsulfonamides as BLT1 antagonists
CA3015744C (en) 2016-03-16 2024-04-23 Basf Se Use of 1-[2-[[1-(4-chlorophenyl)pyrazol-3-yl]oxymethyl]-3-methyl-phenyl]-4-methyl-tetrazol-5-one for combating resistant phytopathogenic fungi on cereals
CA3015456C (en) 2016-03-16 2024-09-17 Basf Se USE OF TETRAZOLINONES TO CONTROL RESISTANT PLANT PATHOGENIC FUNGI ON FRUIT
US11241012B2 (en) 2016-03-16 2022-02-08 Basf Se Use of tetrazolinones for combating resistant phytopathogenic fungi on soybean
KR20190017924A (ko) 2016-06-15 2019-02-20 바스프 아그로 비.브이. 4치환 알켄의 에폭시화 방법
KR20190017926A (ko) 2016-06-15 2019-02-20 바스프 아그로 비.브이. 사치환된 알켄의 에폭시화 방법
GB201803394D0 (en) * 2018-03-02 2018-04-18 Inflazome Ltd Novel compounds
WO2021101927A1 (en) 2019-11-18 2021-05-27 Vanderbilt University Wdr5-myc inhibitors
WO2024040267A2 (en) * 2022-08-19 2024-02-22 Mitokinin, Inc. Direct synthesis of n-(3-substituted-chroman-4-yl)-7h- pyrrolo[2,3-d]pyrimidin-4-amines and derivatives thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3706764A (en) 1969-04-16 1972-12-19 Yoshitomi Pharmaceutical Phenethylaminomethyl-chromanones and- thiochromanones
US3803176A (en) 1969-05-09 1974-04-09 Novo Terapeutisk Labor As Sulfonylurea derivatives
GB1499323A (en) 1974-03-22 1978-02-01 Fisons Ltd 6-substituted chromones and chromanones
DE3275295D1 (en) 1981-11-12 1987-03-05 Fisons Plc Anti-srs-a carboxylic acid derivatives, processes for their production, and pharmaceutical formulation containing them
EP0091749A3 (en) 1982-04-08 1984-12-05 Beecham Group Plc Ethanolamine derivatives, process for their preparation and pharmaceutical compositions containing them
ZA844519B (en) 1983-06-24 1985-02-27 Hoffmann La Roche Dihydrobenzopyran derivatives
US4654362A (en) 1983-12-05 1987-03-31 Janssen Pharmaceutica, N.V. Derivatives of 2,2'-iminobisethanol
DE3411992A1 (de) 1984-03-31 1985-10-10 Bayer Ag, 5090 Leverkusen Substituierte 4-hydroxy-benzopyrane, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
US4727877A (en) * 1984-12-18 1988-03-01 Medtronic, Inc. Method and apparatus for low energy endocardial defibrillation
GB8801306D0 (en) 1988-01-21 1988-02-17 Ici Plc Chemical compounds
US5163427A (en) * 1990-11-14 1992-11-17 Medtronic, Inc. Apparatus for delivering single and multiple cardioversion and defibrillation pulses
US5117824A (en) * 1990-11-14 1992-06-02 Medtronic, Inc. Apparatus for monitoring electrical physiologic signals
US5129392A (en) * 1990-12-20 1992-07-14 Medtronic, Inc. Apparatus for automatically inducing fibrillation
FR2695387B1 (fr) 1992-09-09 1994-10-21 Adir Nouveaux composés benzopyraniques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US5451677A (en) 1993-02-09 1995-09-19 Merck & Co., Inc. Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
ATE154935T1 (de) 1993-06-14 1997-07-15 Pfizer Zweite amine als antidiabetische mittel und für die behandlung von fettleibigkeit
GB9405019D0 (en) 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel compounds
US5541197A (en) 1994-04-26 1996-07-30 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
IL113410A (en) 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them
US5561142A (en) 1994-04-26 1996-10-01 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
US5516917A (en) 1994-06-08 1996-05-14 G. D. Searle & Co. Leukotriene B4 antagonists
JPH08198866A (ja) 1995-01-20 1996-08-06 Tokyo Tanabe Co Ltd 新規２−アミノ−１−フェニルエタノール化合物
US5674254A (en) * 1995-05-22 1997-10-07 Vitatron Medical, B.V. Cardiac pacemaker system and method for determining a measure of pacing threshold without incurring loss of capture
US5663194A (en) 1995-07-25 1997-09-02 Mewshaw; Richard E. Chroman-2-ylmethylamino derivatives
ZA967892B (en) 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
FR2746395B1 (fr) * 1996-03-22 1998-04-17 Adir Nouveaux derives d'arylethanolamine et d'aryloxypropanolamine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP3708624B2 (ja) 1996-03-27 2005-10-19 キッセイ薬品工業株式会社 ３，４−ジ置換フェニルエタノールアミノテトラリンカルボン酸誘導体
EP0801060A1 (en) 1996-04-09 1997-10-15 Pfizer Inc. Heterocyclic Beta-3 Adrenergenic Agonists
JP2000511903A (ja) 1996-06-07 2000-09-12 メルク エンド カンパニー インコーポレーテッド 糖尿病および肥満の治療のための選択性β▲下３▼作動薬としてのオキサジアゾール・ベンゼンスルホンアミド
IL131130A0 (en) 1997-01-28 2001-01-28 Merck & Co Inc Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity
US5741312A (en) * 1997-03-12 1998-04-21 Vitatron Medical, B.V. Pacemaker system and method with improved capture detection and threshold search
US6469031B1 (en) * 1998-12-18 2002-10-22 Bayer Corporation Carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists
US6051586A (en) 1997-12-19 2000-04-18 Bayer Corporation Sulfonamide substituted chroman derivatives useful as beta 3 adrenoreceptor agonists
DK1040106T3 (da) * 1997-12-19 2002-12-02 Bayer Ag Carboxylsubstituerede chromanderivater til anvendelse som beta 3 adrenoreceptor-agonister
US6052621A (en) * 1998-01-27 2000-04-18 Vitatron Medical B.V. System and method for inducing tachycardia
GB9812709D0 (en) 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
WO2000069517A1 (en) * 1999-05-12 2000-11-23 Medtronic, Inc. Monitoring apparatus using wavelet transforms for the analysis of heart rhythms
US6647292B1 (en) * 2000-09-18 2003-11-11 Cameron Health Unitary subcutaneous only implantable cardioverter-defibrillator and optional pacer
US6675042B2 (en) * 2002-04-15 2004-01-06 Charles D. Swerdlow Defibrillation shock strength determination technology

Also Published As

Publication number Publication date
AR035858A1 (es) 2004-07-21
US20050215594A1 (en) 2005-09-29
US6919371B2 (en) 2005-07-19
JP2004532227A (ja) 2004-10-21
EP1389202B1 (en) 2004-09-29
US6660752B2 (en) 2003-12-09
ES2230487T3 (es) 2005-05-01
WO2002085891A1 (en) 2002-10-31
PE20021073A1 (es) 2002-12-12
DOP2002000385A (es) 2004-01-31
US20030078260A1 (en) 2003-04-24
US20040072828A1 (en) 2004-04-15
EP1389202A1 (en) 2004-02-18
DE60201437D1 (de) 2004-11-04

Similar Documents

Publication Publication Date Title
US6660752B2 (en) 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists
TWI588136B (zh) 多環類衍生物、其製備方法及其在醫藥上的應用
DE60120138T2 (de) Amid-verbindungen und deren verwendung
AU2018271343A1 (en) Anthelmintic compounds and compositions and method of using thereof
US6699860B2 (en) Di-substituted aminomethyl-chroman derivative beta-3 adrenoreceptor agonists
EP0298452A2 (de) In 4-Stellung durch Aryl oder N-Heteroaryl substituierte 2H-1-Benzopyran-Derivate
US6780859B2 (en) Benzofuran and dihydrobenzofuran derivatives useful as beta-3 adrenoreceptor agonists
EP0540914A1 (de) 2-Aminomethyl-chromane als Wirkstoffe in Arzneimitteln zur Behandlung von Erkrankungen des Zentralnervensystems
EP1680109A1 (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
TW202300146A (zh) 經三唑基-甲基取代的α-D-吡喃半乳糖苷衍生物
DE69807523T2 (de) Carboxylsubstituierte chromanderivate zur verwendung als beta 3 adrenorezeptor-agonisten
AU751015B2 (en) Novel sulfonamide substituted chroman derivatives useful as beta-3 adrenoreceptor agonists
DE69518322T2 (de) C-4 amid substituierte verbindungen und deren verwendung als therapeutische mittel
US20040072843A1 (en) Novel sulfonamide substituted chroman derivatives useful as beta 3 adrenoreceptor agonists
WO2005066131A1 (en) Non-nucleotide reverse transcriptase inhibitors
US20030013705A1 (en) Novel carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists
DE10120619A1 (de) 2-(5-(4-Fluorphenyl)-3-pyridylmethylaminomethyl-chroman
DE69422038T2 (de) Benzopyranderivate
CZ20002257A3 (cs) Karboxysubstituované chromanové deriváty, které lze použít jako beta-3-adrenoreceptorové agonisty
DE102005039145A1 (de) Substituierte benzokondensierte Cyclohexanon-Derivate und deren Verwendung zur Herstellung von Arzneimitteln
KR20040028769A (ko) 카텝신 억제제로서의 화합물 및 조성물
OA17714A (en) Anthelmintic compounds and compositions and method of using thereof.
HK1034973A (en) Carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee